Study Conduct

Janssen R&D establishes global cross-pharma clinical trial Investigator Databank

Monday, November 19, 2012 10:18 AM

Janssen Research & Development, based in Raritan, N.J., has established a global cross-pharmaceutical Investigator Databank designed to improve efficiencies of industry-sponsored clinical trials. Merck and Eli Lilly are the first two companies to join Janssen in this effort.

More... »

Greenphire chosen for long-term global trial

Wednesday, November 7, 2012 09:17 AM

King of Prussia, Penn.-based Greenphire, a provider of payment technologies for the clinical trials industry, said its ClinCard Technology Platform has been chosen for use in a large, phase III clinical trial to include more than 1,000 patients across six countries. The trial is expected to last more than five years. 

More... »

MMG, Remedy Health to bolster clinical trial enrollment

Wednesday, October 17, 2012 03:46 PM

MMG, a global health communications company specializing in clinical trial patient recruitment and retention, has formed an exclusive partnership with Remedy Health Media, a health information and technology company, to deliver unique access to a larger pool of qualified potential clinical trial participants.

More... »

Clinical research sites honor Eli Lilly, Medpace with Eagle Awards

Monday, October 15, 2012 11:57 AM

The 2012 Eagle Awards, presented to the top sponsor and top CRO as voted by clinical research sites, honored Eli Lilly and Medpace on Saturday, Oct. 13, at the annual Site Solutions Summit.

More... »

Society for Clinical Research Sites launches as voice of site community in shaping research enterprise

Sunday, October 14, 2012 07:00 AM

Clinical research sites now have their first-ever trade group.

More... »

Investigational drugs chosen for major Alzheimer's prevention trial

Thursday, October 11, 2012 07:00 AM

Scientists have selected the first investigational drugs for a worldwide Alzheimer's disease prevention trial. The pioneering study, expected to start by early 2013, initially will test three promising drugs—gantenerumab, solanezumab and an unnamed BACE inhibitor—each designed to target Alzheimer's in different ways.

More... »

Nextrials, InClin partner to provide next gen clinical research services

Wednesday, October 10, 2012 10:38 AM

Nextrials, a clinical research software and services company based in San Ramon, Calif., has formed a partnership with InClin, a specialized CRO of Los Altos, Calif., to provide next generation clinical research services.

More... »

The Medicines Company discontinues phase IIb trial

Friday, October 5, 2012 02:27 PM

The Medicines Company has voluntarily discontinued its phase Iib, dose-ranging study of MDCO-2010, a serine protease inhibitor being developed to reduce blood loss during surgery. This action was taken in response to serious unexpected patient safety issues encountered during the trial, which so far had recruited 44 of a planned 90 patients in the first stage of the study.

More... »

Oramed Pharma, Medpace collaborate on phase II FDA trial of oral insulin

Wednesday, October 3, 2012 10:19 AM

Oramed Ltd., a subsidiary of Oramed Pharmaceuticals, a developer of oral drug delivery systems, has signed an agreement to retain Medpace as a full-service CRO for Oramed's upcoming phase II clinical trial on its oral insulin capsule, ORMD-0801.

More... »

Sanofi selects Bioclinca’s Onpoint as enterprise CTMS

Monday, October 1, 2012 02:15 PM

Pharmaceutical company Sanofi has selected global provider of clinical trial management services BioClinica’s OnPoint as the company’s standard clinical trial management system (CTMS). With this decision, Sanofi plans to utilize OnPoint CTMS for all clinical trial management activity.

More... »